Experimed

SUBMITINFORMATION
EnglishTürkçe

Research Article


DOI :10.26650/experimed.1403563   IUP :10.26650/experimed.1403563    Full Text (PDF)

Effects of GDF-15 Level in Patients with Membranous Nephropathy

Aida Adıkozalova, Sebahat Usta Akgül, Erol Demir, Hayriye Şentürk Çiftçi, Fatma Savran Oğuz, Halil Yazıcı, Çiğdem Kekik Çınar

Objective: Nephrotic syndrome is the most frequent cause of membranous nephropathy (MN) in adults. Growth differentiation factor (GDF)-15 is a cytokine released under stress and associated with increased incidence of chronic kidney disease and/or decreased renal function in conditions such as diabetic nephropathy, IgA nephropathy, lupus nephritis, and primary MN. The diagnosis of MN is made by biopsy, which is an invasive procedure. A non-invasive biomarker is needed for timely and risk-free diagnosis. This study aimed to estimate the GDF-15 level in patients with MN to determine if it can be used as a noninvasive biomarker for the diagnosis of MN.

Materials and Methods: The study included 88 patients with MN. Sera were obtained from peripheral blood collected from the patients. GDF-15 levels were analyzed using enzyme-linked immunosorbent assay (ELISA).

Results: GDF-15 level was high in older patients that in younger patients. The glomerular filtration rate was low in patients with increased GDF-15 levels. Furthermore, a decrease in GDF-15 levels was observed in patients in remission.

Conclusion: GDF-15 level may be used as a biomarker to predict the progression of MN rather than a diagnostic biomarker.

Keywords: Membranous nephropathy, GDF-15, ELISA

PDF View

References

  • Stanescu HC, Arcos-Burgos M, Medlar A, Bockenhauer D, Kottgen A, Dragomirescu L, et al. Risk HLA-DQA1 and PLA2R1 alleles in idiopathic membranous nephropathy. N Engl J Med 2011; 364: 616-26. google scholar
  • Lai WL, Yeh TH, Chen PM, Chan CK, Chiang WC, Chen YM, et al. Membranous nephropathy: a review on the pathogenesis, diagnosis, and treatment. J Formos Med Assoc 2015; 114: 102-11. google scholar
  • Ham YR, Song CH, Bae HJ, Jeong JY, Yeo MK, Choi DE, et al. Growth differentiation factor-15 as a predictor of idiopathic membranous nephropathy progression: a retrospective study. Dis Markers 2018: 1463940. google scholar
  • Wu L, Luo L, Zhou L, Li N, Qin, X. GDF-15 and sST-2 act as biomarkers of disease severity but not independent predictors in idiopathic membranous nephropathy. Int Immunopharmacol 2022; 111: 109150. google scholar
  • Lajer M, Jorsal A, Tarnow L, Parving HH, Rossing P. Plasma growth differentiation factor- 15 independently predicts all-cause and cardiovascular mortality as well as deterioration of kidney function in type 1 diabetic patients with nephropathy. Diabetes Care 2010; 33: 1567- 72. google scholar
  • Ho JE, Hwang SJ, Wollert KC, Larson MG, Cheng S, Kempf T, et al. Biomarkers of cardiovascular stress and incident chronic kidney disease. Clin Chem 2013; 59: 1613-20. google scholar
  • Krintus M, Braga F, Kozinski M, Borille S, Kubica J, Sypniewska G, et al. A study of biological and lifestyle factors, including within-subject variation, affecting concentrations of growth differentiation factor 15 in serum. Clin Chem Lab Med 2019; 57(7): 1035-43. google scholar
  • Hamon S M, Griffin T P, Islam M N, Wall D, Griffin MD, O’Shea PM. Defining reference intervals for a serum growth differentiation factor-15 (GDF-15) assay in a Caucasian population and its potential utility in diabetic kidney disease (DKD). Clin Chem Lab Med 2019; 57(4): 510-20. google scholar
  • Zhu H, Han Q, Zhang D, Wang Y, Gao J, Yang X, et al. The clinicopathological features of patients with membranous nephropathy. Int J Nephrol Renovasc Dis 2018; 11: 33. google scholar
  • Breit SN, Johnen H, Cook AD, Mohammad MG, Kuffner T, Zhanget HP, et al. The TGF-0 superfamily cytokine, MIC-1/GDF15: a pleotrophic cytokine with roles in inflammation, cancer and metabolism. Growth Factors 2011; 29: 187-95. google scholar
  • Lankeit M, Kempf T, Dellas C, Cuny M, Tapken H, Peter T, et al. Growth differentiation factor-15 for prognostic assessment of patients with acute pulmonary embolism. Am J Respir Crit Care Med 2018; 177: 1018-25. google scholar
  • Ferrari N, Pfeffer U, Dell’Eva R, Ambrosini C, Noonan DM, Albini A. The transforming growth factor-0 family members bone morphogenetic protein-2 and macrophage inhibitory cytokine-1 as mediators of the antiangiogenic activity of N-(4-hydroxyphenyl) retinamide. Clin Cancer Res 2005; 11: 4610-19. google scholar
  • Kahli A, Guenancia C, Zeller M, Grosjean S, Stamboul K, Rochette L, et al. Growth differentiation factor-15 (GDF-15) levels are associated with cardiac and renal injury in patients undergoing coronary artery bypass grafting with cardiopulmonary bypass. PloS One 2014; 9(8): e105759. google scholar
  • Frimodt-M0ller M, von Scholten BJ, Reinhard H, Jacobsen PK, Hansen TW, Persson FI, et al. Growth differentiation factor-15 and fibroblast growth factor-23 are associated with mortality in type 2 diabetes-an observational follow-up study. PloS One 2018; 13(4): e0196634. google scholar
  • Kim JS, Kim S, Won CW, Jeong KH. Association between plasma levels of growth differentiation factor-15 and renal function in the elderly: Korean frailty and aging cohort study. Kidney Blood Press Res 2019; 44: 405-14. google scholar
  • Tuegel C, Katz R, Alam M, Bhat Z, Bellovich K, Boer L, et al. GDF-15, galectin 3, soluble ST2, and risk of mortality and cardiovascular events in CKD. Am J Kidney Dis 2018; 72: 519-28. google scholar
  • Breit SN, Carrero JJ, Tsai VWW, Yagoutifam N, Luo W, Kuffner T, et al. Macrophage inhibitory cytokine-1 (MIC-1/GDF15) and mortality in end-stage renal disease. Nephrol Dial Transplant 2012; 27: 70-5. google scholar
  • Zhang W, Chu HC, Xue F. Assessing preoperative plasma growth-differentiation factor- 15 for prediction of acute kidney injury in patients undergoing cardiac surgery. Critical Care 2017; 21: 53. google scholar
  • Short CD, Feehally J, Gokal R, Mallick NP. Familial membranous nephropathy. Br Med J 1984; 289: 1500. google scholar
  • World Health Organization: Nutritional anemias: Report of a WHO Scientific Group. World Health Organ Tech Rep Ser 1968; 405: 5-37. google scholar

Citations

Copy and paste a formatted citation or use one of the options to export in your chosen format


EXPORT



APA

Adıkozalova, A., Usta Akgül, S., Demir, E., Şentürk Çiftçi, H., Savran Oğuz, F., Yazıcı, H., & Kekik Çınar, Ç. (2024). Effects of GDF-15 Level in Patients with Membranous Nephropathy. Experimed, 14(1), 40-45. https://doi.org/10.26650/experimed.1403563


AMA

Adıkozalova A, Usta Akgül S, Demir E, Şentürk Çiftçi H, Savran Oğuz F, Yazıcı H, Kekik Çınar Ç. Effects of GDF-15 Level in Patients with Membranous Nephropathy. Experimed. 2024;14(1):40-45. https://doi.org/10.26650/experimed.1403563


ABNT

Adıkozalova, A.; Usta Akgül, S.; Demir, E.; Şentürk Çiftçi, H.; Savran Oğuz, F.; Yazıcı, H.; Kekik Çınar, Ç. Effects of GDF-15 Level in Patients with Membranous Nephropathy. Experimed, [Publisher Location], v. 14, n. 1, p. 40-45, 2024.


Chicago: Author-Date Style

Adıkozalova, Aida, and Sebahat Usta Akgül and Erol Demir and Hayriye Şentürk Çiftçi and Fatma Savran Oğuz and Halil Yazıcı and Çiğdem Kekik Çınar. 2024. “Effects of GDF-15 Level in Patients with Membranous Nephropathy.” Experimed 14, no. 1: 40-45. https://doi.org/10.26650/experimed.1403563


Chicago: Humanities Style

Adıkozalova, Aida, and Sebahat Usta Akgül and Erol Demir and Hayriye Şentürk Çiftçi and Fatma Savran Oğuz and Halil Yazıcı and Çiğdem Kekik Çınar. “Effects of GDF-15 Level in Patients with Membranous Nephropathy.” Experimed 14, no. 1 (May. 2024): 40-45. https://doi.org/10.26650/experimed.1403563


Harvard: Australian Style

Adıkozalova, A & Usta Akgül, S & Demir, E & Şentürk Çiftçi, H & Savran Oğuz, F & Yazıcı, H & Kekik Çınar, Ç 2024, 'Effects of GDF-15 Level in Patients with Membranous Nephropathy', Experimed, vol. 14, no. 1, pp. 40-45, viewed 4 May. 2024, https://doi.org/10.26650/experimed.1403563


Harvard: Author-Date Style

Adıkozalova, A. and Usta Akgül, S. and Demir, E. and Şentürk Çiftçi, H. and Savran Oğuz, F. and Yazıcı, H. and Kekik Çınar, Ç. (2024) ‘Effects of GDF-15 Level in Patients with Membranous Nephropathy’, Experimed, 14(1), pp. 40-45. https://doi.org/10.26650/experimed.1403563 (4 May. 2024).


MLA

Adıkozalova, Aida, and Sebahat Usta Akgül and Erol Demir and Hayriye Şentürk Çiftçi and Fatma Savran Oğuz and Halil Yazıcı and Çiğdem Kekik Çınar. “Effects of GDF-15 Level in Patients with Membranous Nephropathy.” Experimed, vol. 14, no. 1, 2024, pp. 40-45. [Database Container], https://doi.org/10.26650/experimed.1403563


Vancouver

Adıkozalova A, Usta Akgül S, Demir E, Şentürk Çiftçi H, Savran Oğuz F, Yazıcı H, Kekik Çınar Ç. Effects of GDF-15 Level in Patients with Membranous Nephropathy. Experimed [Internet]. 4 May. 2024 [cited 4 May. 2024];14(1):40-45. Available from: https://doi.org/10.26650/experimed.1403563 doi: 10.26650/experimed.1403563


ISNAD

Adıkozalova, Aida - Usta Akgül, Sebahat - Demir, Erol - Şentürk Çiftçi, Hayriye - Savran Oğuz, Fatma - Yazıcı, Halil - Kekik Çınar, Çiğdem. “Effects of GDF-15 Level in Patients with Membranous Nephropathy”. Experimed 14/1 (May. 2024): 40-45. https://doi.org/10.26650/experimed.1403563



TIMELINE


Submitted13.12.2023
Accepted05.04.2024
Published Online24.04.2024

LICENCE


Attribution-NonCommercial (CC BY-NC)

This license lets others remix, tweak, and build upon your work non-commercially, and although their new works must also acknowledge you and be non-commercial, they don’t have to license their derivative works on the same terms.


SHARE




Istanbul University Press aims to contribute to the dissemination of ever growing scientific knowledge through publication of high quality scientific journals and books in accordance with the international publishing standards and ethics. Istanbul University Press follows an open access, non-commercial, scholarly publishing.